Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma

被引：3
|
作者：
Li, N. [1 ]
Li, Z. [1 ]
Fu, Q. [1 ]
Zhang, B. [1 ]
Zhang, J. [1 ]
Wan, X. [1 ]
Lu, C. [1 ]
Wang, J. [1 ]
Deng, W. [1 ]
Wei, C. [1 ]
Ma, Y. [1 ]
Bie, L. [1 ]
Wang, M. [1 ]
Luo, S. [1 ]
机构：
[1] Zhengzhou Univ, Dept Internal Med, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.181
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
160P
引用
收藏
页码：S1302 / S1302
页数：1
相关论文
共 50 条
  • [1] Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li Ning
    Li Zhi
    Fu Qiang
    Zhang Bin
    Zhang Jian
    Wan XiangBin
    Lu Chaomin
    Wang Jinbang
    Deng Wenying
    Wei Chen
    Ma Yijie
    Bie Liangyu
    Wang Mengyu
    Luo Suxia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] Efficacy and safety of FLOT combined with apatinib and sintilimab as a neoadjuvant therapy regimen for locally advanced gastric or gastroesophageal junction adenocarcinoma: An open-lable, single-arm, phase II study
    Zhou, H.
    Long, B.
    Yu, Z.
    Zhu, J.
    Yang, H.
    Zhang, W.
    Guan, X.
    Zhang, G.
    Li, L.
    Luo, C.
    Cao, H.
    Zhang, S.
    Chen, S.
    He, Q.
    Gan, S.
    Zhou, L.
    Jiang, X.
    Shi, W.
    Huang, Z.
    Mao, J.
    Dong, C.
    Jiao, Z.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S66 - S67
  • [3] Response to neoadjuvant chemotherapy in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma with FLOT-regimen in our setting
    Garcia Grove, C.
    Gallego Jimenez, I.
    Martinez Bernal, G.
    Miras Rodriguez, I.
    Limon Miron, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S119 - S119
  • [4] Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
    Li, Hongli
    Deng, Jingyu
    Ge, Shaohua
    Zang, Fenglin
    Zhang, Le
    Ren, Peng
    Wang, Baogui
    Cao, Fuliang
    Deng, Ting
    Liu, Rui
    Ning, Tao
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Duan, Jingjing
    Liu, Yong
    Zhou, Dejun
    Liang, Han
    Ba, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study
    Chalabi, M.
    Verschoor, Y. L.
    Van De Haar, J.
    van den Berg, J.
    Kodach, L.
    van Sandick, J.
    van Dieren, J.
    Balduzzi, S.
    Grootscholten, M. C.
    Veenhof, X.
    Hartemink, K.
    Vollebergh, M.
    Owers, E.
    Bartels-Rutten, A.
    den Hartog-Lievaart, P.
    van Leerdam, M.
    Schumacher, T. N.
    Haanen, J. B. A. G.
    Voest, E. E.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1106 - S1106
  • [6] Efficacy and safety of cadonilimab combined with FLOT regimen as a neoadjuvant therapy for locally advanced gastric/gastroesophageal junction adenocarcinoma: A prospective, multicenter, open-label, single-arm phase II study
    Long, B.
    Zhou, H.
    Wei, D.
    Yang, T.
    Chai, N.
    Yu, Z.
    Yang, H.
    Guan, X.
    Zhang, W.
    Chen, S.
    Zhou, L.
    Jiang, X.
    Shi, W.
    Huang, Z.
    Zhu, J.
    Luo, C.
    Mao, J.
    Dong, C.
    Jiang, Z.
    Zhao, X.
    Zhao, D.
    Jiao, Z.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S70 - S71
  • [7] Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, Ning
    Li, Zhi
    Fu, Qiang
    Zhang, Bin
    Zhang, Jian
    Wan, XiangBin
    Lu, Chaomin
    Wang, Jinbang
    Deng, Wenying
    Wei, Chen
    Ma, Yijie
    Bie, Liangyu
    Wang, Mengyu
    Luo, Suxia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Wei, J.
    Lu, X.
    Liu, Q.
    Li, L.
    Liu, S.
    Liu, F.
    Fu, Y.
    Fan, X.
    Yang, J.
    Yang, Y.
    Zhao, Y.
    Guan, W.
    Liu, B.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1316
  • [9] Epirubicin, oxaliplatin, and docetaxel (EOD) combination in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A phase II study
    Di Lauro, L.
    Giacinti, L.
    Arena, M. G.
    Fattoruso, S. I.
    Foggi, P.
    Lopez, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A phase II study of bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer
    El-Rayes, B. F.
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Heilbrun, L. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345